MedTrace Logo

Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients

NCT03341741 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2017-11-14

No results posted yet for this study

Summary

To assess whether the inhalative combination of Tobramycin/Colistin is more effective in reducing Pseudomonas colony forming units (CFUs) and improvement of lung function than Colistin in mono-therapy.

Conditions

  • Cystic Fibrosis With Pulmonary Manifestations

Interventions

DRUG

Tobramycin Powder

TOBI®Podhaler 2 x 112 mg daily for 2 x 28 days (on/off);

DRUG

Colistin

Colistin solution 2 x daily 1 Mega continuously

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-11
Primary Completion
2015-12-19
Completion
2016-11-25

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03341741 on ClinicalTrials.gov